BSETrident Texofab LtdHighNeutral
Announced Thu, 29 May · 20:17 IST

Financial Result for the Quarter and year ended on March 31, 2025

Revenue Growth 20pctPat Growth 25pctEbitda Margin ExpansionExceptional ItemResults View source PDF

Price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reaction · full curve

Awaiting price reaction for this filing.

AI summary

Trident Texofab Limited reported its audited standalone results for FY25, with revenue from operations rising to Rs. 12,205.62 lakhs from Rs. 9,948.34 lakhs in FY24, a growth of about 22.7%. Profit after tax jumped sharply to Rs. 251.01 lakhs (FY24: Rs. 107.98 lakhs), up roughly 132%. Q4 FY25 alone saw revenue of Rs. 3,820.63 lakhs (vs Rs. 3,017.12 lakhs in Q4 FY24) and a PAT of Rs. 51.05 lakhs, compared to a small loss of Rs. 10.25 lakhs in the year-ago quarter. The statutory auditor, Shah Kailash & Associates LLP, issued an unmodified opinion on the results. The Board also approved the conversion of 4,50,477 warrants into equity shares at Rs. 70 each, raising about Rs. 2.37 crore, taking paid-up equity capital to Rs. 14.51 crore (1.45 crore shares). Additionally, M/s. Purushottam Khandelwal & Co. was appointed as Internal Auditor for FY25-26.

Likely market impact

Strong topline and bottomline growth, return to profitability in Q4, and a clean audit opinion are positive signals for shareholders. The warrant conversion causes minor equity dilution but also brings in fresh capital, supporting business expansion.